CVS improves clinical decision-making with revised Clinical Advisory Committee supported by twelve new Subject Matter Working Groups
CVS Group is improving clinical decision-making for its companion animal division with the launch of a revised Clinical Advisory Committee, supported by twelve new Subject Matter Working Groups.
CVS’ Clinical Advisory Committee is responsible for supporting the delivery and continuous improvement of its high standard of care right across general practice and referrals hospitals sites.
CVS’ new Clinical Advisory Committee and Subject Matter Working Groups are one of a number of initiatives to improve clinical decision-making that the veterinary profession can read about the company’s latest Quality Improvement Report.
The aim is to make clear and transparent appraisals of treatments and equipment and include a wide group of colleagues with a broad base of experience representing all types of clinical roles in our practices.
Twelve new Subject Matter Working Groups have also been created - representing the major veterinary subject areas of Anaesthesia, Cardiology, Dentistry, Dermatology, Diagnostic Imaging, ECC, Exotic Medicine, Medicine, Ophthalmology, Surgery, Oncology and Neurology - to offer experience and expertise when making clinical decisions.
Their remit will be to: provide technical knowledge and feedback on clinical policy; review and appraise the evidence supporting new-to-market therapies; identify and share the most important clinical developments; provide technical knowledge and feedback on equipment; regular review and update clinical guidelines; and, disseminate the clinical decision-making process.
Over 90 clinicians are now part of these Subject Matter Working Groups, actively contributing to the clinical direction of CVS Group.
Small Animal Veterinary Director Lizzie McLennan-Green, said:
CVS Group operates across small animal, farm animal, equine, laboratories and crematoria, with over 500 veterinary practices and referral centres in the UK, the Republic of Ireland, the Netherlands and Australia. In the last five years the company has invested nearly £80 million in its sites, facilities and equipment, in addition to industry leading training and support, to give the best possible care to animals.